NCT07376603 IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
| NCT ID | NCT07376603 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qiaojuan Guo |
| Condition | Nasopharyngeal Cancinoma (NPC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 169 participants |
| Start Date | 2026-01-12 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 169 participants in total. It began in 2026-01-12 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone in patients with stage IB nasopharyngeal carcinoma (NPC) without high-risk features. The primary objective is to determine the therapeutic effectiveness of this approach
Eligibility Criteria
Inclusion Criteria: 1\. Histopathologically confirmed, newly diagnosed nasopharyngeal carcinoma 3. Age 18-70 years 4. Stage IB disease (T1-2N1M0) per the 9th edition AJCC/UICC staging system 5. Upper-neck nodal metastasis only: inferior border of every positive node at or above the inferior border of the hyoid bone 6. ECOG performance status 0-2 7. Adequate bone-marrow function Exclusion Criteria: 1. Age \> 70 years or \< 18 years 2. Matted lymph nodes: two or more contiguous nodes with loss of intervening fat planes and/or extracapsular extension forming a confluent mass 3. Largest metastatic lymph-node ≥ 3 cm in the longest dimension 4. Lower-neck nodal metastasis: inferior border of any positive node below the inferior border of the hyoid bone 5. Prior malignancy except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix 6. Pregnancy or lactation (serum pregnancy test required for women of child-bearing potential; effective contraception mandatory during treatment) 7. Previous radiotherapy to the head-and-neck region 8. Prior chemotherapy or surgery for the primary tumour or metastatic nodes (diagnostic procedures excluded) 9. Any severe comorbidity that would confer unacceptable risk or compromise protocol adherence, including but not limited to unstable cardiac disease, renal failure, chronic hepatitis, or uncontrolled psychiatric disorder 10. History of severe hypersensitivity reactions
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07376603 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Nasopharyngeal Cancinoma (NPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07376603 currently recruiting?
Yes, NCT07376603 is actively recruiting participants. Contact the research team at fjzlec@163.com for enrollment information.
Where is the NCT07376603 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07376603 clinical trial?
NCT07376603 is sponsored by Qiaojuan Guo. The trial plans to enroll 169 participants.